Cannas Giovanna, Elhamri Mohamed, Thomas Xavier
Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, 5, place d'Arsonval, 69437, Lyon Cedex 03, France.
Constitutive Reference Center: Major Sickle Cell Syndromes, Thalassemia and Other Rare Pathologies of Red Blood Cell and Erythropoiesis, Edouard Herriot Hospital, Lyon, France.
Oncol Ther. 2024 Jun;12(2):233-238. doi: 10.1007/s40487-024-00274-7. Epub 2024 Mar 29.
Sickle cell disease (SCD) is a severe monogenic hereditary hemoglobinopathy that is characterized by repeated clinical and biological manifestations able to generate stress erythopoiesis. A clonal hematopoiesis involving mainly variants of TP53, DNMT3A, ASXL1, and/or TET2 may be more prevalent in patients with SCD, suggesting that mutations in these genes may lead to an increased risk of leukemia. An increased prevalence of leukemia in patients with SCD has been confirmed by an increasing number of acute myeloid leukemia cases with myelodysplastic features reported in this patient population even in the absence of disease-modifying treatments. This leads to the hypothesis of a mechanism involving multifactorial causes through the pathophysiologic manifestations of SCD, in which cells are undergoing constant hematopoietic hyperplasia, inducing genomic damage and somatic mutations.
镰状细胞病(SCD)是一种严重的单基因遗传性血红蛋白病,其特征是反复出现能够引发应激性红细胞生成的临床和生物学表现。主要涉及TP53、DNMT3A、ASXL1和/或TET2变异的克隆性造血在SCD患者中可能更为普遍,这表明这些基因的突变可能导致白血病风险增加。即使在没有疾病修饰治疗的情况下,该患者群体中报告的具有骨髓增生异常特征的急性髓系白血病病例数量不断增加,这证实了SCD患者中白血病患病率的增加。这导致了一种假说,即通过SCD的病理生理表现涉及多因素原因的机制,其中细胞正在经历持续的造血增生,诱导基因组损伤和体细胞突变。